ORIG3N, Inc.
Records under this name other than patents ORIG3N, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,101,360 | IL-1 Gene Cluster, Insulin Resistance and Coronary Artery Disease Associated Polymorphisms and Haplotypes and Methods of Using Same Formerly held In force · High confidence | In force | High confidence | |
| US 9,347,090 | Method for Determining Severity and Progression of Periodontal Disease Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,842,822 | Diagnosis and treatment of parkinson's disease based on identification and amelioration of liver dysfunction Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,340,875 | Systems and methods for automated monitoring and replenishment of genetic material reserves Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,615,866 | Systems and methods for automated monitoring and replenishment of genetic material reserves Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,087,399 | Systems and methods for customizing cell culture media for optimized cell proliferation based on genetic traits of cells Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,692,174 | Systems, methods, and apparatus for induced pluripotent stem cell isolation and combinatorial production Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 12,114,840 | DNA Collection Device Formerly held In force · High confidence | In force | High confidence | |
| US 12,115,037 | Systems and Methods of Assisted Reproduction and Prevention of Genetic Defects in Offspring Using Induced Pluripotent Stem Cells Formerly held In force · High confidence | In force | High confidence | |
| US 7,723,028 | Diagnostics and Therapeutics for Osteoporosis Term ended Term ended Jun 21, 2022 · Medium confidence | Term ended | Term ended Jun 21, 2022 | Medium confidence |